Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Stoke Therapeutics, Inc. (STOK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Stoke Therapeutics, Inc. Consolidated balance sheets June 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 192,060 $ 113,556 Marketable securities 39,387 116,039 Prepaid expenses 10,950 10,932 Other current assets 3,699 2,955 Interest receivable 136 588 Total current assets $ 246,232 $ 244,070 Restricted cash 569 569 Operating lease right-of-use assets 3,646 4,753 Property and equipment, net 6,472 6,675 Total assets $ 256,919 $ 256,067 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,556 $ 766 Accrued and other current liabilities 12,222 15,748 Deferred revenue - current portion 8,059 14,880 Total current liabilities $ 21,837 $ 31,394 Deferred revenue - net of current portion 43,258 36,856 Other long term liabilities 1,629 2,968 T..."
03/06/2023 8-K Quarterly results
Docs: "Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates – Company expects to complete Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome in 2023 in order to initiate a Phase 3 program in 2024 –"
11/14/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
Docs: "Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – 2H 2022 clinical data readout on track for patients with Dravet syndrome who received multiple doses of STK-001 in Phase 1/2a clinical studies MONARCH, ADMIRAL, and SWALLOWTAIL –"
11/08/2021 8-K Quarterly results
Docs: "Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – Company nominates STK-002 as clinical candidate for the treatment of autosomal dominant optic atrophy , the most common inherited optic nerve disorder –"
05/10/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company ...",
"Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates"
08/10/2020 8-K Quarterly results
05/15/2020 8-K Quarterly results
Docs: "Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Company on track to begin enrollment and dosing of STK-001 in Part A of Phase 1/2a “Monarch” clinical trial in children and adolescents with Dravet syndrome in 2H 2020 –"
03/23/2020 8-K Quarterly results
Docs: "STOKE THERAPEUTICS Reports FULL YEAR 2019 financial results and provides business updateS"
11/12/2019 8-K Quarterly results
08/14/2019 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company ...",
"STOKE THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE BEDFORD, Mass. — — August 14, 2019 — Stoke Therapeutics, Inc., , a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the second quarter of 2019. “We are making efficient and meaningful progress toward our goal of delivering the first medicine to target the underlying cause of Dravet syndrome, a severe and progressive form of epilepsy. In the past year, we have strengthened our team, advanced the development of our TANGO technology, and bolstered our financial position through our recent successful IPO,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutic..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy